# An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

> **NCT04089553** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 59 (actual)

## Conditions studied

- Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** AZD4635
- **DRUG:** Oleclumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04089553
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-29
- **Primary completion:** 2021-06-16
- **Final completion:** 2023-04-11
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089553, "An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04089553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*